Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FDEK7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $16,584.13 to DMS Pharmaceutical Group Inc. for STELARA 90 mg/mL syringes on November 13, 2025, with an ultimate completion date of December 5, 2025. DMS Pharmaceutical Group is a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, and a critical supplier within the federal pharmaceutical supply chain. This delivery order was issued without a set-aside designation under a firm fixed-price contract structure, demonstrating the company's competitive capability in unrestricted federal procurement.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) designated SPE2DR with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a ceiling value of $499,999,999 and an ultimate completion date of December 31, 2036. The PPV-G GEN V program is part of a broader $30.3 billion acquisition strategy that establishes regional prime vendor contractors to supply pharmaceuticals, biologics, and medical consumables to Department of Defense healthcare facilities worldwide. The contract structure enables DLA to issue multiple firm fixed-price delivery orders for specialized pharmaceutical products to support recurring military medical supply needs, with this particular order for STELARA representing one of numerous deliveries the vendor has executed as part of its comprehensive product portfolio spanning oncology treatments, immunosuppressants, vaccines, and routine pharmaceuticals.
Quick answers
Who was awarded contract SPE2DR26FDEK7?
SPE2DR26FDEK7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 13, 2025.
How much is contract SPE2DR26FDEK7 worth?
The government has obligated $16,584 on SPE2DR26FDEK7.
Is contract SPE2DR26FDEK7 an order under another contract?
Yes. SPE2DR26FDEK7 is a delivery order under SPE2DR25D9112, an indefinite delivery contract.
Was contract SPE2DR26FDEK7 competed?
The extent of competition for SPE2DR26FDEK7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award